寿 T REGNASE-1

Jun Wei1, Lingyun Long1, Wenting Zheng2

  • 1Department of Immunology, St Jude Children's Research Hospital, Memphis, TN, USA.

Nature
|December 13, 2019
PubMed
まとめ

REGNASE- 1をターゲットにすることで,CD8+ T細胞を長寿命のエフェクタ細胞に再プログラムし,がんの免疫療法を大幅に改善します. このアプローチはT細胞の持続性と機能を高め,臨床前モデルの治療効果を高めます.

関連する概念動画

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K